Technical Analysis for ALXO - ALX Oncology Holdings Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Historical ALXO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Calm After Storm | Range Contraction | 1.85% | |
| Upper Bollinger Band Walk | Strength | 1.85% | |
| Upper Bollinger Band Touch | Strength | 1.85% | |
| Shooting Star Candlestick | Bearish | -2.18% | |
| Calm After Storm | Range Contraction | -2.18% | |
| Upper Bollinger Band Walk | Strength | -2.18% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Fell Below Previous Day's Low | 2 days ago | |
| Up 3% | 2 days ago | |
| Up 2% | 2 days ago | |
| Up 1% | 2 days ago | |
| Down 3% | 3 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Solid Tumor Myelodysplastic Syndromes CD47
Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Solid Tumor Myelodysplastic Syndromes CD47
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 51.1 |
| 52 Week Low | 28.01 |
| Average Volume | 167,458 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 40.32 |
| 20-Day Moving Average | 38.27 |
| 10-Day Moving Average | 40.24 |
| Average True Range | 3.33 |
| ADX | 18.89 |
| +DI | 24.33 |
| -DI | 16.16 |
| Chandelier Exit (Long, 3 ATRs ) | 36.66 |
| Chandelier Exit (Short, 3 ATRs ) | 42.49 |
| Upper Bollinger Band | 44.18 |
| Lower Bollinger Band | 32.37 |
| Percent B (%b) | 0.8 |
| BandWidth | 30.86 |
| MACD Line | 0.92 |
| MACD Signal Line | 0.25 |
| MACD Histogram | 0.6676 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 44.34 | ||||
| Resistance 3 (R3) | 44.26 | 43.31 | 43.91 | ||
| Resistance 2 (R2) | 43.31 | 42.66 | 43.36 | 43.77 | |
| Resistance 1 (R1) | 42.54 | 42.25 | 42.07 | 42.62 | 43.62 |
| Pivot Point | 41.59 | 41.59 | 41.36 | 41.64 | 41.59 |
| Support 1 (S1) | 40.82 | 40.94 | 40.35 | 40.90 | 39.90 |
| Support 2 (S2) | 39.87 | 40.53 | 39.92 | 39.75 | |
| Support 3 (S3) | 39.10 | 39.87 | 39.61 | ||
| Support 4 (S4) | 39.18 |
